Device Trial Radar · NCT06114992
Servo-n HFOV Study: Safety and Performance in Neonates and Infants
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Jul 15, 2024
Primary completion
Apr 14, 2026
Study completion Jul 3, 2026
Sponsor
- Lead sponsor
- Maquet Critical Care ABNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- NAMSA; Paediatric and Neonatal Mechanical Ventilation (PNV) Consulting
- First posted
- Nov 2, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and performance of High-Frequency Oscillatory Ventilation (HFOV) modes of the Servo-n ventilator in neonates and infants, by using a prospective, observational, single-arm (i.e., non-controlled) and multi-center Post-Market Follow-up (PMCF) study design. HFOV treatment will be evaluated by assessing ventilation and oxygenation variables, and safety will be evaluated by documentation of device related adverse events.
Conditions
- Elective HFOV for Respiratory Failure in Neonates/Infants
- Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy
Interventions
Servo-n HFOV modesDevice
Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects that achieved and/or maintained target ranges for oxygenation, as measured by preductal Saturation of Peripheral Oxygen (SpO2).Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
- Proportion of subjects that achieved and/or maintained target ranges for ventilation as measured either by Partial Pressure of Carbon Dioxide (PCO2) (if available blood gas) or Transcutaneous Carbon Dioxide (TcCO2)Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
- Proportion of subjects that maintained or improved values for oxygenation as measured by the SpO2/FiO2 ratio and/ or achieved target ranges for oxygenation (preductal SpO2)Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
1 more outcomes with a free account
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
CHU Montpellier-Arnaud de Villeneuve
Montpellier, France
Antoine-Béclère Hospital
Paris, France
Poznan University of Medical Sciences
Poznan, Poland
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.